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Abstract
Patients afflicted with ulcerative colitis (UC) are at increased risk of
colorectal cancer. While its causes are not fully understood, UC is
associated with defects in colonic epithelial barriers that sustain inflam-
mation of the colon mucosa caused by recruitment of lymphocytes and
neutrophils into the lamina propria. Based on genetic evidence that
attenuation of the bridging integrator 1 (Bin1) gene can limit UC
pathogenicity in animals, we have explored Bin1 targeting as a therapeutic
option. Early feasibility studies in the dextran sodium sulfate mouse model
of experimental colitis showed that administration of a cell‐penetrating
Bin1 monoclonal antibody (Bin1 mAb 99D) could prevent lesion formation
in the colon mucosa in part by preventing rupture of lymphoid follicles. In
vivo administration of Bin1 mAb altered tight junction protein expression
and cecal barrier function. Strikingly, electrophysiology studies in organ
cultures showed that Bin1 mAb could elevate resistance and lower 14C‐
mannitol leakage across the cecal mucosa, consistent with a direct
strengthening of colonic barrier function. Transcriptomic analyses of
colitis tissues highlighted altered expression of genes involved in circadian
rhythm, lipid metabolism, and inflammation, with a correction of the
alterations by Bin1 mAb treatment to patterns characteristic of normal
tissues. Overall, our results suggest that Bin1 mAb protects against UC by
directly improving colonic epithelial barrier function to limit gene
expression and cytokine programs associated with colonic inflammation.
KEYWORD S
circadian rhythm, inflammatory bowel disease (IBD), immunotherapy, inflammation, tight
junctions, ulcerative colitis (UC), Bin1 monoclonal antibody
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1 | INTRODUCTION
Ulcerative colitis (UC) is a chronic, idiopathic
inflammatory disease that affects the colon, most
commonly afflicting adults aged 30 to 40 years.
Patients with UC have mucosal inflammation starting
in the rectum that often extends continuously to
proximal segments of the colon. UC usually presents
with bloody diarrhea and is diagnosed by colonoscopy
and histological findings.1
People with UC have a higher risk of developing
colorectal cancer.2 The colorectal cancer risk is as high
as 18% with 30 years of UC. The increased risk of
colorectal cancer is due in part to the inflammation‐
induced loss of barrier function. As yet there are no
fully effective drugs or therapies to protect against UC.
The inflammatory cytokines, tumor necrosis factor
(TNF)‐α, and IFN‐γ are elevated in UC. While anti‐
inflammatory drugs and immune suppressors (eg,
TNF‐α inhibitors) are currently prescribed for UC
treatment, side effects such as the risk of opportunistic
infections and the lack of efficacy in certain individuals
limit the quality of treatment. Hence, there is an
interest in developing additional immunotherapies to
provide protection against UC.3
The bridging integrator 1 (Bin1), also known as
amphiphysin 2, is a nucleocytoplasmic adaptor protein
with 10 isoforms. BIN1 was initially identified in 1996
as a tumor suppressor; subsequently, however, addi-
tional functions have been attributed to different
protein transcripts. Bin1 is a conserved member of
the BAR (Bin‐Amphiphysin‐Rvs) family of adapter
proteins implicated in diverse cellular processes
including endocytosis, actin organization, programmed
cell death, stress responses, and transcriptional con-
trol.3 The BIN1 gene has recently been identified as the
most important risk locus for late‐onset Alzheimerʼs
disease, after apolipoprotein E.4
In a recent study, our group demonstrated that
genetic attenuation of Bin1 reduced disease severity in
a mouse model of experimental colitis occurring in
association with an enhancement of epithelial barrier
function.5 On the basis of that study, we explored the
ability of Bin1 monoclonal antibodies (mAb) developed
by our group to phenocopy effects of genetic attenua-
tion in the colitis model. We recently reported the
development of a novel colitis therapy targeting the
Bin1 protein and supporting epithelial barrier func-
tion3. We used both cell culture and animal models for
the study. In this article, we report progress in the
identification of the mechanism by which Bin1 mAb
provides protection in UC.
2 | MATERIALS AND METHODS
2.1 | Bin1 mAb
Two Bin1 mAb investigated in this study that was developed
in our laboratory previously are designated 99D and 2F11.
The antibody 99D recognizes an epitope within the
C‐terminal Myc binding domain encoded by exon 13,
whereas antibody 2F11 recognizes an epitope within the N‐
terminal BAR domain encoded by exons 7 and 8. Although
both antibodies specifically recognize Bin1 isoforms, only
99D was found to exert therapeutic activity in applications to
reduce colitis morbidity in mice. 99D also exhibited the
ability to improve barrier function as demonstrated by in
vitro experiments with human Caco2 colon cells. 2F11 was
used for western blot analyses in both settings.3
2.2 | Experimental colitis model system
For the study, we used a therapeutic animal model of UC.
Animals were weighed before, during, and after treat-
ments. Male mice (C57BL/6) of 5 weeks of age were fed
with 3% dextran sodium sulfate (DSS; Alfa Aesar; MW
40 kDa) in drinking water ad libitum (n = 5 per group).
After 7 days of DSS treatment, mice were provided with
distilled water. Twenty‐four hours after feeding with
water they were injected ip (0.5 mg of purified antibody
per mouse) with Bin1 mAb or antibody isotype control.3
Animals on the long‐term study were injected with a
second dose of the Bin1 mAb or antibody isotype control
14 days after the first dose. After 7, 14, and 28 days of
Bin1 mAb or isotype control treatments, mice were
euthanized and colons were measured and inspected for
necropsy for gross macroscopic lesions and used to
determine the protein levels by western blot analysis.
The animal studies were approved by the Institutional
Care and Use Committee of the Lankenau Institute for
Medical Research and performed in accordance with
their guidelines under an approved animal protocol.
2.3 | Electrophysiology and epithelial
permeability measurements
Evaluation of transepithelial electrical resistance (TER) and
transepithelial mannitol flux was done as described pre-
viously.6 The mouse cecum was used for analysis in this
study due to its larger size facilitating Ussing chamber
studies. At necropsy, the cecum was isolated by dissection,
sliced longitudinally, and cleaned by ice‐cold pH 7.35
bicarbonate buffered saline (Krebs-Ringer bicarbonate,
KRB). This tissue was then laid on its mucosal surface and
the serosal membrane and muscularis propria were surgi-
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cally removed. Remaining tissue was mounted on 1.13 cm2
Ussing chamber and the tissue bathed in 37°C KRB stirred
by gas‐lift (95% O2, 5% CO2) oxygenation. This chamber
permits the separation and sampling of luminal versus
antiluminal fluid compartments, thereby allowing the precise
study of transport and barrier function by the epithelium.
TER and transepithelial voltage were measured every
2minutes using Ag/AgCl electrodes in series with 1M NaCl
agar bridges and a standard current/voltage clamp delivering
1 second pulses of 40 μA direct current (McGrath Research
and Technology, Phoenix, AZ). After 30 to 45minutes of
incubation, the mucosal tissue was physiologically stabilized
and the maximal TER was measured (greater TER values
indicate lower electrolyte permeability). Short‐circuit current
and potential difference measurements were also performed
using this apparatus. 14C‐mannitol (Perkin‐Elmer, Boston,
MA) along with nonradiolabeled mannitol was then added
to the mucosal Hemi chamber (final activity 0.1 μCi/ml, final
concentration 0.1mM). Aliquots from the serosal fluid Hemi
chamber were taken every 15minutes for 60minutes for
liquid scintillation counting. From linear regression of a
graph of cpm per unit time, and using the measured specific
activity of the nonmetabolizable 14C‐mannitol in the mucosal
Hemi chamber, we calculated the transepithelial probe flux
rate (pmol min−1 cm−2 tissue). This value reflects the
permeability of the TJs to D‐mannitol.6
2.4 | Western blot analysis
Bin1 mAb treated or control colons were dissected into upper
and lower colon. Mucosal tissue was physically scraped and
lysed as previously described.7 After polyacrylamide gel
electrophoresis (10% gel) and transfer to nitrocellulose
membrane, they were probed with antibodies for claudin
proteins (Claudin‐2, ‐3, and ‐5; 1‐2 µg mL−1; Life Technol-
ogies, CA) according to the manufacturerʼs instructions.
2.5 | RNA‐seq analysis
Twelve RNA samples from four groups, control (ctr), DSS
treated, IgG, or Bin1 antibody treated, were first treated with
Invitrogen/Ambion DNA‐free kit (cat #AM1906) to remove
DNA and run on the Agilent 2100 Bioanalyzer for quality
assessment. The sequencing libraries were generated using
the Lexogen QuantSeq 3′ mRNA sequencing library
preparation kit (SKU:015.24) for Illumina sequencing plat-
form compatible libraries. The KAPA real‐time PCR Library
Quantification Kit (KK4835) was used to quantify and assess
library quality. All libraries were pooled in equal molar
amounts and run on an Illumina NextSeq 500 using the Mid
Output V2 (150 cycles) kit (cat # FC‐404‐2001) in a 75 base
pair single read run. Raw reads were aligned using bowtie 2
algorithm7 against mm10 genome, and Ensembl transcrip-
tome information was used along with RSEM software8 to
calculate raw read counts for each gene. Differential
expression analysis was done using DESeq2.9 Genes
significantly affected by DSS treatment (false discovery rate
[FDR]< 10%) as compared with controls were considered
and genes with expression significantly rescued by Bin1 over
IgG antibody (P<0.05) were taken for enrichment analysis.
Expression data for top changed genes were visualized in a
heatmap using Microsoft Excel. Analysis of the gene set for
the enrichment of Upstream Regulators was done using
QIAGENʼs Ingenuity Pathway Analysis software (IPA,
QIAGEN Redwood City; www.qiagen.com/ingenuity). Only
regulators with targets significantly enriched at least P<10−7
and activation state predicted with Z‐score of at least 1 were
reported.
2.6 | Antibody array
Male mice (C57BL/6) of 5 weeks of age were fed with 3%
DSS (Alfa Aesar, MW 40 kDa) in drinking water ad
libitum (n = 2‐3 per group). After 7 days of DSS
treatment, mice were provided with distilled water.
Twenty‐four hours after feeding with water they were
injected ip (0.5 mg per mouse) with Bin1 mAb or
antibody isotype control. Mice were euthanized and
colons were measured and inspected for necropsy for
gross macroscopic lesions on day 7 after injection with
Bin1 mAb or isotype control. Tissues were then homo-
genized in RIPA buffer and protein concentration was
quantified with a BCA protein assay kit (Pierce). The
concentration of 40 mouse cytokines and chemokines
was analyzed with Mouse Quantibody Cytokine Arrays
Q5 (QAM‐CYT‐4000; RayBiotech) by the RayBiotech
testing service, according to manufacturerʼs instructions.
Briefly, samples were incubated with slides preprinted
with the 40 respective capture antibodies. A standard
mix, consisting of known amounts of recombinant
proteins representing all 40 proteins were used to
quantify the concentration of every cytokine. Sample
incubation was followed by extensive washing to remove
any nonbound proteins in the sample matrix. Next, a
biotinylated detection antibody cocktail was incubated on
the array. After washing away unbound biotinylated
detection antibodies, the arrays were incubated with a
fluor‐conjugated with streptavidin and the fluorescent
signals were visualized using a fluorescent scanner
(InnoScan 710; InOpsys ). Inter‐ and intra‐slide normal-
ization of fluorescent signal intensities was conducted
using positive controls consisting of biotin‐labeled IgG,
and negative controls, consisting of buffer only. Average
signal intensities of quadruplicate spots, minus outliers,
were used for all calculations. Outliers were determined
as values over 30% above the average signal intensity
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across the quadruplicate spots. Data below the lower
limit of detection were discarded.
2.7 | Immunohistochemistry
Caco2 BBE cells (passages 55–63), an epithelial cell line
derived from human colon carcinoma, were obtained from
American Type Culture Collection (CRL‐ 2102). The method
of Wang et al10 was followed for culture and maintenance of
cells. Sixty percent confluent cells were treated with Bin1
mAb or isotype control for 48 hours and the cells stained
following the method of Rybakovsky et al.11 The cells were
probed with the primary antibodies: EEA1, Beclin‐1,
Sequestosome1/p62, CD32, and ubiquitinylated antibodies
(1:500; Thermo Fisher Scientific, MA); followed by the
secondary antibodies anti‐rabbit Alexa 488/592, anti‐mouse
Cy3 (1:500) and DAPI. The cells were mounted using
Fluoromount‐G (Southern Biotech, AL) and visualized by
confocal microscopy (Nikon Eclipse TI, Japan). Images were
taken from different fields from the same slide. The
experiments were repeated three times.
2.8 | Statistical analyses
Unpaired two‐tailed Student t tests were used to compare
sets of data obtained from independent groups of animals.
Statistical significance was considered at the P<0.05 level.
3 | RESULTS
3.1 | Bin1 mAb 99D protects colon
mucosa in an animal model of UC
DSS‐induced colitis is commonly used to address the
pathogenesis of inflammatory bowel disease (IBD). We
demonstrated recently that the Bin1 mAb (99D) could
provide protection in the DSS murine model of UC.3 We
determined previously that a single administration of
0.5 mg Bin1 mAb was the optimum dosage to prevent
colitis. Previously,3 we reported on the histology of the
colon during Bin1 mAb treatment after the induction of
colitis; hence, they are not reported in this article. In this
article, we further investigated the biological effects and
mechanism of action of the therapeutic effect. In the
design used, mice were administered with 3% DSS in
FIGURE 1 Bin1 antibody treatment
altered the weight of mice. There was a
change in weight of mice treated with
Bin1 mAb after subjecting to DSS
treatment of 7 days (*P< 0.05, **P< 0.01,
***P< 0.001 as determined by t test). Bin1,
bridging integrator 1; DSS, dextran
sodium sulfate; mAb, monoclonal
antibodies
FIGURE 2 Bin1 antibody treatment
altered the length of the colon. There was
a change in length of the colon of mice
treated with Bin1 mAb after subjecting to
DSS treatment of 7 days. (*P< 0.05 as
determined by t test). Bin1, bridging
integrator 1; DSS, dextran sodium sulfate;
mAb, monoclonal antibodies
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water for 7 days (standard protocol) followed by
providing distilled water. Animals develop colitis within
7 days of treatment with DSS. Twenty‐four hours after
feeding with water the animals were injected with 0.5 mg
of Bin1 mAb or nonspecific murine IgG (isotype‐matched
to 99D). The other controls included mice that were
untreated or DSS‐only treated mice. We performed both
short‐term and long‐term treatments. Short‐term studies
involved treating DSS exposed animals with Bin1 mAb
for 7 or 14 days. In long‐term studies, animals exposed to
DSS were given two doses of Bin1 mAb that were 14 days
apart, with the animals euthanized on day 28 after the
first dose.
Mice treated with Bin1 mAb did not lose weight after
exposure to DSS. The Bin 1 mAb treated animals
exhibited greater weight on days 7, 14 and 28 compared
to control subjects that were untreated or treated with
IgG (Figure 1). As expected, DSS‐induced erosion of the
colon tissue structure and thereby impacted the physiol-
ogy and metabolism of the animals. However, in
protecting animals from colitis, Bin1 mAb administration
specifically prevented the characteristic weight loss
induced by DSS treatment.
In animals exposed to DSS there is a significant
decrease in colon length.5 Hence, colon length measure-
ment has been used as a morphological parameter of the
degree of tissue damage in DSS colitis.12 In our study,
mice from each group were euthanized on days 7, 14, and
28 post mAb treatment and the colon dissected and
measured. Mice treated with Bin1 mAb had significantly
longer colons on days 7 and 14 compared with the IgG‐
treated or DSS alone controls (Figure 2). In contrast,
there was no significant change in the length of colons
isolated from mice up to 28 days after Bin1 mAb
treatment, consistent with a mitigating effect of the
treatment on the manifestation of colitis in the model.
3.2 | Bin1 mAb treatment improves
basal intestinal barrier function
To investigate the effects of targeting of Bin1 with the
99D antibody on intestinal epithelial cell barrier function,
we used an established organ culture system using
murine cecal colon segments.13 Specifically, cecal seg-
ments from mice were dissected and mounted in Ussing
chambers to measure mucosal barrier function by
FIGURE 3 Colon of mice treated
with Bin1 mAb had A, high resistance
and B, low flux compared to the controls.
Bin1, bridging integrator 1; mAb,
monoclonal antibodies
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electrophysiology and 14C‐mannitol flux.13 (At a given
time, only four tissues could be analyzed in our
laboratory. Hence, the treatments [Bin1 mAb and IgG]
were compared against DSS/PBS sections at different
time periods.) Because mannitol has no affinity for
membrane transporters, its movement across epithelia is
essentially only through the paracellular pathway. The
Bin1 mAb‐treated mice had a higher basal cecal TER
compared with the control mice treated with IgG isotype
(Figure 3A). Consistent with this observation, there was
also a lower transepithelial flux of 14C‐mannitol across
the cecum in Bin1 mAb‐treated mice compared with the
mice treated with the isotype control (Figure 3B). These
observations supported the notion that systemic admin-
istration of the Bin1 mAb could phenocopy the effects of
Bin1 genetic attenuation,13 and also that it directly
affected colon epithelial barrier function in vivo.
3.3 | Bin1 mAb treatment impacts the
colon tight junction proteins
In our previous study we used a cell culture model of
Caco2 BBe and demonstrated that Bin1 mAb induced
changes in tight junction proteins. In this study, the colon
of the euthanized mice was divided into proximal and
distal halves. Each was lysed and subjected to western
blot analysis. Initially, we probed the levels of the Bin1
protein in the proximal and distal colon using the 2F11
Bin1 antibody. There was a low expression of the
Bin1 protein in the proximal and distal colon of Bin1
mAb‐treated animals compared with the controls.
Similarly, the expression of the pore‐forming claudin‐2
was lower in the Bin1 mAb‐treated mice exposed to DSS
compared with controls on days 7, 14, and 28 in the
proximal as well as distal colons. However, the Bin1
treated mice exposed to DSS had higher expression of
claudin‐3 and ‐5 in both the proximal and distal colons
on days 7, 14, and 28 compared with controls. The results
demonstrated that Bin1 mAb increased the expression of
the tight junction barrier proteins that may protect
against colitis (Figure 4A‐C; Supporting Information
Figures 1‐3).
3.4 | Altered gene expression patterns
induced by DSS are corrected by Bin1 mAb
treatment
To determine genes significantly affected by Bin1 mAb, we
assayed transcriptome expression changes using RNA‐seq.
We found 209 genes that were significantly affected in DSS
mice vs control (FDR<10%) and after 7 days of Bin1 mAb
treatment. The top 32 most significantly changed genes are
shown in Figure 5A. Bin1 mAb treatment increased the
expression of genes negatively related to obesity. Bin1 mAb
treatment upregulated adiponectin, adipsin (complement
factor D), carbonic anhydrase 3 (Car3), and thiosulfate
sulfurtransferase (TST) involved in obesity, whereas they are
decreased during colitis (Figure 5A).
Bin1 mAb treatment increased the expression of
UGDH (involved in regulating inflammation) as well as
Sepp1 and Spint2 (involved in inhibiting colon cancer
induced during inflammation). The cytochromes are
involved in the metabolism of drugs. Bin1 mAb treatment
increased the expression of the genes Cytochrome P450
(Cyp4f16), Sulfotransferase family 1B member 1 (Sult1b)
involved in drug metabolism.
Environmental triggers such as sleep disorders could
impact disease course in IBD.14 Circadian rhythms in gene
expression are regulated at the cellular level by a molecular
clock comprising a core set of clock genes/proteins. The
genes involved in lipid biosynthesis and fatty acid oxidation
FIGURE 4 The expression of Bin1 and claudins in the distal
and proximal colon of mice after the induction of colitis on days
A, 7 days; B, 14 days; and C, 28 days after the treatment with Bin1
mAb. Bin1, bridging integrator 1; mAb, monoclonal antibodies
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are rhythmically activated and repressed by clock proteins,
hence providing a direct mechanism for circadian regulation
of lipids. DSS‐induced colitis leads to the increase in the
expression of genes involved in circadian rhythm (Noct/
nocturnin and cyp2d26/ Cytochrome P450 2D26) and
sphingolipid metabolism (ESYT1/Extended Synaptotagmin
1); whereas, Bin1 mAb treatment lowered their expression.
Bin1 mAb treatment lowered the expression of genes
involved in inducing inflammation including, Tifa,
Trim15, Tac1, Adm, Socs3, Ly6a, Lrg1, and Clca4b.
Bin1 mAb treatment also lowered the expression of
regenerating family member 3 gamma and Pla2g2a.
REGs and Pla2g2a are highly expressed during IBD.15,16
We also analyzed the list of 209 genes to determine the
genes altered by the treatment with Bin1 mAb. Using
Ingenuity Pathway Analysis17-19 we found five regulators
(Figure 5B) with a significant number of known targets in
the list and whose activity was predicted to be activated
upon Bin1 mAb treatment. Of the eight regulators
predicted to be inhibited by Bin1 mAb, five were
cytokines, including TNF, IL‐1B, IFN‐γ, OSM, and IL‐
22. Bin1 mAb activates PPARA, PPARG, and IL‐10RA
known to have anti‐inflammatory effects.
3.5 | Bin1 mAb treatment reduces the
expression of inflammatory cytokines
Currently, TNF‐inhibitors are used in the treatment of UC.
These inhibitors are known to lower the expression of
inflammatory cytokines. We determined the expression of
the cytokines using RayBiotech antibody arrays. Bin1 mAb
lowered the expression of inflammatory cytokines including
FIGURE 5 Gene expression analysis results. A, Top genes most significantly affected by DSS (FDR< 10%) and significantly rescued by
Bin1 mAb (FDR1 < 0%). B, Ingenuity Pathway Analysis results with upstream regulators that have a significant number of targets (N) in the
list of 209 genes. Activation Z‐scores (Z) calculated by IPA based on targets mRNA changes predicts the activity of regulatory proteins.
Bin1, bridging integrator 1; DSS, dextran sodium sulfate; FDR, false discovery rate
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TNF‐α, TWEAK (TNF family), and IFN‐γ. The expression of
the cytokines, IL‐2, ‐3, ‐4, ‐5, ‐7, ‐9, ‐10, ‐21, ‐23, and IL‐12p70
was also decreased on treatment with the Bin1 mAb. These
cytokines are known to be inducers of UC and other IBD
diseases. The expression of the T‐cell co‐stimulatory
molecules CD27 and OX‐40L, as well as the expression of
the monocytes/macrophages co‐stimulatory molecule SLAM,
is reduced on treatment with the Bin1 mAb. The apoptosis
molecules Fas and FasL are upregulated in UC. However,
Bin1 mAb treatment led to the lower expression of these
molecules after the induction of DSS‐induced colitis in mice
(Figure 6).
3.6 | Bin1 mAb is taken into cells by
multiple mechanisms
Bin1 is a protein localized on the membrane and in the
cytosol. In our study, Bin1 mAb efficacy assumes
intracellular access of the Ab. It is however clearly not
understood how the Bin1 mAb is taken into cells. In this
study and our previous study,3 we demonstrated that
Bin1 mAb could lower the expression of Bin1 protein in
colon epithelial cells. To determine how the Bin1 mAb is
taken into cells we incubated Caco2 cells in the presence
of Bin1 mAb and analyzed by confocal microscopy how
they are taken into cells.
Endosomes are involved in the transport of nutrients
as well as microorganisms into cells.20 Recently, we
observed high expression of the endosomal proteins
EEA1 and Beclin‐1 in the mucosal and muscularis region
of mouse colon.21 On the basis of this data we
hypothesized that the endosomes in the colon may be
involved in compartmentalizing the host microbiome to
prevent entry into the tissues. To determine if the
endosomes are also observed in the Caco2 cells, we
cultured the cells and observed the expression of the early
endosomal protein EEA1 at 70% confluence. Most of the
EEA1 endosomes were localized on the margins of the
Caco2 cells (Figure 7A). The Bin1 mAb was localized to
the EEA1 endosomal proteins.
To determine if other endosomal proteins are coloca-
lized with the Bin1 mAb, we probed for Beclin‐1 and
sequestosome/p62. Analysis of Caco2 cells incubated
with Bin1 mAb by confocal microscopy demonstrated
colocalization of Beclin‐1 and sequestosome/p62 with the
Bin1 mAb supporting that the Bin1 mAb could be taken
into the cells by endosomes (Figure 7B and 7C).
In neuronal cells, Gu et al22 and Congdon et al23
demonstrated antibody entry mediated by Fc gamma
receptor endocytosis. Caco2 cells were incubated in the
presence of Bin1 mAb or isotype controls for 48 hours
and probed with Fc gamma RII (CD32). Caco2 exhibits
heterogeneity, with a different subpopulation of cells
during cell culture.24 We observed that not every cell of
the cultured Caco2 incorporated Fc gamma RII (CD32).
Those cells exhibiting Fc gamma RII had Bin1 mAb
antibody colocalized with it as observed by the overlap of
the antibody and the receptor (Figure 7D). Our studies
show that multiple intracellular and extracellular pro-
teins are involved in the uptake of Bin1 mAb into cells,
FIGURE 6 Antibody array analysis data. Proteins significantly
reduced by Bin1 mAb (FDR< 5%). The difference of concentration
of proteins between Bin1 mAb and all other groups was tested
using two‐tail two‐sample t test and nominal P values were
corrected for multiple testing using the Benjamini‐Hochberg
method. Proteins that were significantly reduced with FDR< 5%
were considered. Bin1, bridging integrator 1; mAb, monoclonal
antibodies; FDR, false discovery rate
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but most important, that Bin1 mAb has access to
intracellular targets.
4 | DISCUSSION
The Bin1 protein is localized in several tissues, including
the large intestine.25 In a recent article we reported that
administration of DSS to mice induced severe lesions
throughout the mucosa, rupture of the lymphoid follicle,
high‐level neutrophil, and lymphocyte infiltration into
the mucosal and submucosal areas, and loss of surface
crypts; whereas treatment with Bin1 mAb reduced colitis
morbidity. In vitro studies in human Caco2 cells showed
that Bin1 antibody altered the expression of tight junction
proteins and improved barrier function indicating at least
some direct effect on the epithelium. Our data suggested
that a therapy based on Bin1 monoclonal antibody
supporting mucosal barrier function and protecting the
integrity of the lymphoid follicle could offer a novel
strategy to treat UC and possibly limit risks of colorectal
cancer. However, the mechanism by which Bin1 mAb
protects the animals against colitis is not known.3
Bin1 mAb treatment lowered the expression of the Bin1
protein in the proximal and distal colon (Figure 4A and 4B),
demonstrating that the Bin1 mAb was effective in lowering
the specific protein levels in the animals. This infers access of
the mAb to the cell interior. The colon of the DSS treated
mice was shorter and had a bloody stool after 7 days of
treatment; whereas, treatment with Bin1 mAb protected
against colitis. There was no blood in the stool and the nature
of the colon was similar to the untreated controls. To
determine the leakiness of the colon we measured the TER
as well as mannitol permeability. Bin1 mAb‐treated mice
displayed an elevation in basal TER as well as a correspond-
ing decrease in mannitol permeability, both of which directly
implicated improvement of barrier function. Tight junctions
form the apical‐most unit of the epithelial barrier, defining
the boundary between the apical and basolateral membranes
and are predominantly the rate‐limiting factor in the
paracellular passage. The tight junction is built up by both
transmembrane proteins such as occludin, tricellulin,
different claudins, and junctional adhesion molecules, as
well as intracellular proteins such as zonula occludens ‐1, ‐2,
‐3 and cingulin.26 Western blot analysis demonstrated high
expression of the tight junction proteins claudins‐3 and ‐5
after the treatment with Bin1 mAb. The expression of the
pore‐forming claudin‐2 is increased in UC,27 and the
expression is decreased on treatment with the Bin1 mAb
(Figure 4A and 4B).
FIGURE 7 Colocalization of Bin1 mAb with endosomal and Fc gamma receptor proteins in Caco2 cells observed by confocal
microscopy. Bin1 mAb is colocalized (orange) with A, EEA1; B, Beclin‐1; C, p62/sequestosome; and D, CD32 (Fc gamma RII). Bin1, bridging
integrator 1; mAb, monoclonal antibodies
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The incidence of UC is highest in the western hemi-
sphere28; however, recent studies show that the incidence of
UC is increasing in developing countries.29,30 The Western
diet pattern is dominated by increased consumption of
refined sugar, omega‐6 polyunsaturated fats, and fast food,
combined with a diet deficient in fruit, vegetables, and fiber.
This shift to the Western diet pattern is hypothesized to
increase proinflammatory cytokines, modulate intestinal
permeability, and alter the intestinal microbiota promoting
a low‐grade chronic inflammation in the gut.
Lipids have emerged as important components of cellular
signal transduction pathways. Their roles in modulating host
inflammatory responses are of clinical interest as agents of
both promotion and resolution. Dietary lipids are implicated
in the pathogenesis of chronic intestinal inflammation,
including IBD. Perturbations in lipid metabolism could
contribute to the development of IBD.31,32 Biologically active
sphingolipids, such as sphingosine‐1‐phosphate (S1P) are
important regulators of lipid metabolism. S1P is derived from
the recycling of endogenous human sphingolipids and the
metabolism of dietary animal products containing sphingo-
lipids. S1P signals through a family of five G protein‐coupled
receptors. In addition, it activates nuclear factor kappa B
(NF‐κB) and signals transducer and activator of transcription
3, two transcriptional regulators that serve as master switches
in inflammation and carcinogenesis. Through these and
other mechanisms, a causal role for S1P in inflammatory
conditions including UC and colorectal cancer has been
implicated.32,33 Phospholipase A2 (PLA2) is a group of
enzymes that hydrolyze phospholipids to liberate fatty acids
and lysophospholipids, representing the first rate‐limiting
step in the biosynthesis of a variety of lipid mediators. UC
involves the synthesis of eicosanoids from arachidonic acid,
which is released from membrane phospholipids by PLA2.34
Clinical and biochemical evidence suggests that secreted
PLA2 group III (sPLA2‐III) is associated with colorectal
cancer. PLA2 KO mice are less susceptible to DSS‐induced
colitis and are highly resistant to colon carcinogenesis
implying that the amelioration of colonic inflammation by
sPLA2‐III ablation may underlie the protective effect against
colon cancer.34 Our data show that Bin1 mAb treatment
reduces the expression of PLA2, whereas untreated animals
with colitis had high levels of PLA2 (see Figure 5A).
In IBD, obesity is associated with worsening of the course
of the disease. Obesity is a complex disease involving
dysbiosis of the gut microbiota, lipid accumulation, and
insulin resistance.35 Obesity, adipose inflammation, and
malfunction of β cells are tightly associated with one
another, but the molecular link remains to be established.36
Increasing adiposity is directly correlated with adipose
inflammation and elaboration of proinflammatory cytokines
such as TNF‐α.37 Until recently, the role of fat in the
development of obesity was considered to be a passive one.
Adipocytes were considered storage cells for fat. However, a
current view is that adipocytes are a critical component of
metabolic control and function as endocrine organs that have
both good and bad effects. Small adipocytes in lean
individuals promote metabolic homeostasis; the enlarged
adipocytes of obese individuals recruit macrophages and
promote inflammation and the release of a range of factors
that predispose toward insulin resistance.38 The proteins and
cytokines that regulate the adipose tissue may be pro‐ or anti‐
inflammatory. Car3 is an abundant protein in adipose tissue
and it decreases with obesity.39 Similarly, transgenic over-
expression of TST in adipocytes protected mice from diet‐
induced obesity and insulin‐resistant diabetes. TST‐deficient
mice showed markedly exacerbated diabetes, whereas
pharmacological activation of TST ameliorated diabetes in
mice.40 Our RNA array data show that DSS exposure
decreases the expression of the genes involved in obesity;
whereas, Bin1 mAb treatment upregulates the gene expres-
sion (Car3, TST).
Several studies support associations among sleep, im-
mune function, and inflammation.41 As yet it is not known
whether lack of sleep contributes to IBD. Recently, there has
been an increased interest in the roles that sleep, circadian
rhythms, and melatonin could have as regulators of
inflammation in the GI tract. Advances in our understanding
of the molecular machinery of the circadian clock and the
discovery of clock genes in the GI tract are opening up new
avenues of research for a role of sleep in IBD. Altering
circadian rhythm significantly worsens the development of
colitis in animal models, and preliminary human studies
have shown that patients with IBD are at increased risk for
altered sleep patterns.42 A recent study demonstrated that
melatonin may be clinically applicable for patients with IBD,
particularly those suffering from sleep disturbances.43
Our studies show that UC could lead to changes in the
genes of the circadian clock. The genes involved in the
circadian rhythm (Nocturnin, Cytochrome P450 2D26) are
altered by Bin1 mAb treatment demonstrating that the
antibody could influence these genes (see Figure 5A). The
circadian timing system plays a key role in regulating lipid
metabolism. The circadian system ensures that daily rhythms
in lipid absorption, storage, and transport are temporally
coordinated with rest activity and feeding cycles. At the
cellular level, genes involved in lipid synthesis and fatty acid
oxidation are rhythmically activated and repressed by core
clock proteins. In mammals, the core clock components are
CLOCK, BMAL, PER, and CRY.44 Mice with a mutated
CLOCK gene were prone to develop hypertriglyceridemia. A
key role in the regulation of lipid metabolism was
determined for Nocturnin, a gene expressed in a circadian
manner, whose product is an enzyme with a deadenylase
activity. Nocturnin‐deficient mice on a high‐fat diet did not
increase their body weight and visceral fat and did not
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develop fatty liver, without increasing their activity rate or
decreasing food intake. Nocturnin affects lipid metabolism or
uptake, together with glucose and insulin sensitivity.45,46
Sleep deprivation can lead to increased levels of inflamma-
tory cytokines, including IL‐1β, IL‐6, TNF‐α, and C‐reactive
protein, which can lead to further activation of the
inflammatory cascade.41,47
Bin1 mAb treatment increased the expression of PPARA
and PPARG that are involved in regulating inflammation.
The genes are also involved in the regulation of TNF‐α. The
expression of peroxisome proliferator‐activated receptor
gamma, a negative regulator of NF‐κB‐dependent inflamma-
tion, is reduced in the colonocytes of patients with UC,
suggesting a causal link to the disease.1
The current therapies in UC involve the use of systemic
TNF‐α inhibitors that lower the circulating levels of TNF‐
α.48,49 In our studies, we demonstrate that colitis induction
upregulates the expression of the genes of many inflamma-
tory cytokines. These cytokines were also increased when
probed with our antibody arrays. However, the expression of
the genes of the inflammatory cytokines (TNF, IL‐1B, IFN‐γ,
OSM, and IL‐22) was lowered after treatment with the Bin1
mAb. Bin1 mAb activated PPARA, PPARG, and IL‐10RA,
each known to have anti‐inflammatory effects. As an
enhanced inflammatory cytokine profile is a hallmark of
UC, Bin1 mAb may be used to lower the expression of these
cytokines thereby protecting against this disease.
As yet, the mechanism by which antibody enters cells
is not known. In this paper, we demonstrated that
multiple pathways are involved in the uptake of Bin1
mAb into cells. We used Caco2 cells to determine the
mechanism by which the Bin1 mAb is taken into cells.
We demonstrated that the Bin1 mAb is taken up by Fc
gamma RII (CD32). We also observed that endosomes are
involved in the uptake of the antibody. The EEA1
endosomes were observed localized to the periphery of
groups of cells. The EEA1 endosomes have multiple roles
in cells to protect against invading microbes as well as for
the transport of molecules into cells. We recently
demonstrated that the EEA1 is localized in the mucosal
and muscularis layer of the colon.21 We now show that
the endosomal proteins EEA1, Beclin‐1, and sequesto-
some/p62 are also involved in the uptake of Bin1 mAb.
The cytochromes are involved in the metabolism of
drugs. Bin1 mAb treatment increased the expression of the
genes Cyp4f16 (Cytochrome P450), Sult1b involved in drug
metabolism. Once the antibody is taken in, it is cleaved into
peptides and taken into the nucleus where the fragments
are ubiquitinylated and taken out for recycling. Using
confocal microscopy we probed for the ubiquitination after
treatment with the Bin1 mAb. We took z stack of Caco2
and tilted at different angles. We observed ubiquitinated
peptides either associated with Beclin‐1 or independent of
Beclin‐1. The Beclin‐1 protein was chimney‐shaped
FIGURE 8 Expression of ubiquitination in the cytoplasm and nucleus of Caco2 cells by confocal microscopy after incubation with Bin1
mAb. A, Caco2 cells treated with Bin1 mAb shows ubiquitination in the cytoplasm and nucleus. The Beclin‐1 endosomes of the nucleus are
ubiquitinated (orange); (B,C) 3D reconstruction of the z stack of Caco2 cells treated with Bin1 mAb tilted at different angles. The Beclin‐1
has a chimney‐like (fougaro) structure in the nucleus and the ubiquitinylated peptides are colocalized with Beclin‐1 or observed
independently after treatment with the Bin1 mAb. Bin1, bridging integrator 1; mAb, monoclonal antibodies
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(fougaro; Greek, chimney) with the ubiquitinated peptides
associated with it (Figure 8A‐C). In our study, the fougaro
structures were observed vertically in the nucleus; never
horizontal. The fougaro system may be a mechanism to
recycle or remove molecules from the nucleus to the
external medium. To our knowledge, this is the first report
of the fougaro structures composed of Beclin-1 and
associated with the ubiquitinated peptides in the nucleus.
Our study both offers a potential new immunotherapeutic
for UC and demonstrates that multiple factors may be
involved in the development of UC. Lack of sleep or sleep
disorders could lead to altered circadian rhythms that could
lead to poor lipid metabolism. The altered circadian rhythms
could then induce inflammatory cytokines that lead to UC.
Earlier, IBD diseases were confined only to older adults and
reported to be rare in children. However, currently, the
disease is prevalent in children and young adults.50
Interestingly, this demographic group is very active in social
media, study for longer hours, have a diet rich in sugar and
fat and sleep less, factors that may lead to IBD diseases.
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